• Dyne Therapeutics posted a net loss of USD 120.85 million for the quarter ended March 31, 2026, widening from USD 115.36 million a year earlier.
• Operating loss widened to USD 125.28 million as total operating expenses rose to USD 125.28 million, driven by a jump in general and administrative costs to USD 24.39 million.
• Research and development expense slipped to USD 100.89 million, with spending on z-rostudirsen climbing to USD 37.75 million while z-basivarsen costs fell to USD 14.78 million.
• Cash, cash equivalents and marketable securities totaled USD 972.2 million at March 31, 2026, with management expecting existing resources to fund operations into first quarter 2028.
• Company reiterated plans to submit a BLA for z-rostudirsen in second quarter 2026, start a global confirmatory Phase 3 trial in second quarter 2026, and report registrational expansion cohort data for z-basivarsen in first quarter 2027 to support a potential accelerated-approval filing in early third quarter 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dyne Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-215702), on May 11, 2026, and is solely responsible for the information contained therein.